	Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study. J Ovarian Res Roos Alexander H, Afrin Ruma S, Jain S, Lundin E, Liv P, Israelsson P, Pettersson K, Idahl A. PMID: 42215983 [PubMed - indexed for MEDLINE]
	Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations. BMC Cancer Wiguna IGWW, Sadeva IGKA, Mamangdean CT, Mahayana NPK, Khanaruksombat S, Thu MS, Putri PMWS, Tungga KMK, Kepakisan ABN, Arta KIP, Pratama RP, Hirankarn N. PMID: 42215937 [PubMed - as supplied by publisher]
	Exercise-related genes predicts overall survival and tumor immune microenvironment, and identifies the biological role of SLC52A2 in breast cancer. Discov Oncol Chen C, Han C, Xue L, Lu X. PMID: 42215809 [PubMed - as supplied by publisher]
	Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results. NPJ Breast Cancer Bellet M, Ferrero-Cafiero JM, Bergamino Sirvén M, Falato C, González X, Amillano K, Chic N, Morales S, Gasol A, Nuciforo P, Villacampa G, Villagrasa P, Diep CH, Seelig D, Lange C, D'Assoro A, Prat A, Pascual T, Saura C. PMID: 42215464 [PubMed - as supplied by publisher]
	Comment on "The Meaning of Surveillance in Women With a Hereditary Risk of Breast Cancer: A Hermeneutic Phenomenological Study". J Clin Nurs Kumar K V V, Kshirsagar P, Mishra M, Panwar S. PMID: 42215305 [PubMed - as supplied by publisher]
	Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial. ESMO Open Filis P, Liu X, Matikas A, Untch M, Steger GG, Johansson H, Hellström M, Gnant M, Loibl S, Brandberg Y, Bergh J, Foukakis T. PMID: 42215159 [PubMed - indexed for MEDLINE]
	Exploring synchronous endometrial and ovarian cancers. BMJ Case Rep Zaheer S, Agrawal A, Swain S, Ansari HA. PMID: 42215058 [PubMed - indexed for MEDLINE]
	Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial. Ann Oncol Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, International Breast Cancer Study Group, POSITIVE Trial Consortium. PMID: 42214557 [PubMed - as supplied by publisher]
	Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study. Breast Pontolillo L, Munzone E, Vigneri P, Pistelli M, Palazzo A, La Verde N, Mazzotta M, Paris I, Alesini D, Santini D, Cannita K, Orlandi A, Magnolfi E, Giacinti L, Raffaele M, Carbognin L, Santoro A, Rossi A, Arcuri G, Sangalli C, Garrone O, Mulè A, Valenza C, Berardi R, Tortora G, Bria E, Curigliano G, Giannarelli D, Fabi A. PMID: 42214155 [PubMed - as supplied by publisher]
	Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA). JCO Glob Oncol Ntekim A, Popoola A, Sowunmi A, Olasehinde O, Sanni A, Ibraheem A, Zheng Y, Yoshimatsu TF, Dosunmu GT, Omoleye O, Folasire A, Adeniji-Sofoluwe A, Omisore A, Adewumi A, Olajide T, Lawal R, Komolafe A, Omodele F, Ajani M, Michael O, Balogun B, Ale OK, Irurhe N, Folorunso S, Oyekan A, Kotila O, Aniagwu T, Odetunde A, Ilona S, Ajani AO, Oshin A, Onitilo A, Asuzu C, Daramola A, Abdulkareem F, Balogun OO, Karrison T, Babalola P, Huo D, Olopade CO, Obafunwa J, Ojengbede O, Olopade OI. PMID: 42214048 [PubMed - indexed for MEDLINE]
	Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Glob Oncol Peres Moreira RJ, Bines J, Dhungana A, Freeman JQ, Saha P, Sullivan ME, Yao K, Flores EM, Huo D, Pearson AT, Small IA, Olopade OI, Howard FM. PMID: 42214047 [PubMed - indexed for MEDLINE]
	Machine learning models based on magnetic resonance imaging for predicting Lymphovascular Invasion in Invasive Breast Cancer. PLoS One Li H, Huang J, Hou J, Chen X, Zhi C, Li Z. PMID: 42213726 [PubMed - indexed for MEDLINE]
	Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors. J Natl Cancer Inst Russo RG, Hernán MA, Dahabreh IJ, Rimm EB, Veiga LHS, Hurson AN, Curtis RE, Pfeiffer RM, Booker QS, Corley ME, Mitra PR, Ryerson AB, Honda S, White L, Feigelson HS, Aiello Bowles EJ, Roger VL, Ramin C, Barac A, Gierach GL, Danaei G, Vo JB. PMID: 42213587 [PubMed - as supplied by publisher]
	Increased mortality in polycystic ovary syndrome- a cohort study. Eur J Endocrinol Piltonen TT, Koskenkari N, Koivuaho E, Morin-Papunen L, Hurskainen E, Gissler M, Arffman RK, Ollila MM. PMID: 42213411 [PubMed - indexed for MEDLINE]
	Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast Cancer Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T. PMID: 42213365 [PubMed - as supplied by publisher]
	Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment. Appl Health Econ Health Policy Pham TH, de Braak S, van der Werf S, Khoirunnisa SM, Pan X, Pfob A, Wondimu A, van der Schans J, Postma MJ, van Asselt ADI, de Jong LA. PMID: 42213316 [PubMed - as supplied by publisher]
	The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer. Ann Surg Oncol Stanczyk M, Cheung TC, Lang JE. PMID: 42213262 [PubMed - as supplied by publisher]
	Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. Curr Treat Options Oncol Weiner-Gorzel K, McSorley L, Walshe JM. PMID: 42213241 [PubMed - indexed for MEDLINE]
	Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers. Clin Appl Thromb Hemost Zhao Y, Sun X, Lin B, Xu S, Gao H. PMID: 42212702 [PubMed - indexed for MEDLINE]
	Directly comparing randomized and real-world controls in adjuvant breast cancer. J Comp Eff Res Walker B, Boyd M, Silver M, Shi J, Bulsara P, Balanchivadze N, Robert NJ. PMID: 42212589 [PubMed - as supplied by publisher]

Articles 1 - 20 / 329465

Page 1 of 16474



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy